Express Scripts Holding Co (ESRX)

ESRX (NASDAQ:Health Services) EQUITY
$84.94
pos +0.15
+0.18%
Today's Range: 84.35 - 85.19 | ESRX Avg Daily Volume: 3,956,000
Last Update: 03/02/15 - 3:59 PM EST
Volume: 2,603,841
YTD Performance: 0.14%
Open: $84.39
Previous Close: $84.79
52 Week Range: $64.64 - $88.83
Oustanding Shares: 726,898,000
Market Cap: 61,451,956,920
6-Month Chart
TheStreet Ratings Grade for ESRX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 12 12 12
Moderate Buy 3 3 3 3
Hold 6 5 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.73 1.63 1.55 1.55
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 32.02
Price Earnings Comparisons:
ESRX Sector Avg. S&P 500
32.02 32.00 26.52
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
2.98% 13.72% 59.83%
GROWTH 12 Mo 3 Yr CAGR
Revenue -3.10 1.19 0.29
Net Income 8.70 0.60 0.17
EPS 17.90 0.05 0.02
Earnings for ESRX:
EBITDA 5.85B
Revenue 100.89B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $1.10 $1.35 $5.43 $6.01
Number of Analysts 11 13 15 14
High Estimate $1.11 $1.38 $5.49 $6.19
Low Estimate $1.08 $1.32 $5.37 $5.72
Prior Year $0.99 $1.23 $4.88 $5.43
Growth Rate (Year over Year) 10.74% 10.13% 11.37% 10.51%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Bullish
May 13, 2013 | 7:59 AM EDT
ESRX was upgraded from Hold to Buy, Jefferies said. $74 price target. Uncertainty is gone and the company should resume share repurchas...
Bullish
May 01, 2013 | 8:06 AM EDT
ESRX estimates were raised through 2014, BMO Capital said. Company continues to execute on its plan. Market Perform rating and new $62 ...
Express Scripts and McKesson could both see weakness.

A Tale of Two Drugstores Real Money Pro($)

For Walgreen, 2012's bad news was good news, while CVS remains an attractive investment choice.
Bullish
Feb 28, 2013 | 8:17 AM EST
ESRX estimates were boosted through 2014, Citigroup said. Company is keeping a tight lid on costs. Buy rating and new $64 price target....
These two solid names are finding support at their longer-term moving averages.
Bullish
Feb 20, 2013 | 7:57 AM EST
Shares of ESRX now seen reaching $65, according to Lazard Capital Markets. Estimates also upped, given better operating trends. Buy rat...
It’s much tougher to actually “buy low to sell high” than it is to espouse the concept.

Value Seekers, Don't Chase Real Money Pro($)

ESRX still has a a historically low valuation.

Three Names to Watch Real Money Pro($)

This market is rewarding finding the trade early.

Columnist Conversations

Nails a couple of oils that are in deep trouble; must read
After the close Oak announced a 4 million share offering and the shares are getting hit down to $50.10. I am n...
Very solid day to start March as equities tack on to their gains from February. Appreciate the shout out from ...
I know these long-term care guys. You do not want to own these stocks..

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.